CLINICAL RESEARCH
The Effect of Variable Dose and Release Kinetics on Neointimal Hyperplasia Using a Novel Paclitaxel-Eluting Stent Platform
The Paclitaxel In-Stent Controlled Elution Study (PISCES)
Patrick W. Serruys, MD, PhD, FACC*,*,
Georgios Sianos, MD, PhD*,
Alexandre Abizaid, MD ,
Jiro Aoki, MD*,
Peter den Heijer, MD, PhD ,
Hans Bonnier, MD, PhD ,
Pieter Smits, MD, PhD||,
Dougal McClean, MD¶,
Stefan Verheye, MD, PhD#,
Jorge Belardi, MD**,
Jose Condado, MD,
Michel Pieper, MD,
Louise Gambone, BA,
Marco Bressers, MSc||||,
Janette Symons||||,
Eduardo Sousa, MD and
Frank Litvack, MD, FACC
*Erasmus Medical Center, Rotterdam, the Netherlands
Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
Amphia Ziekenhuis, Bredathe Netherlands
Catharina Ziekenhuis, Eindhoventhe Netherlands
|| Medisch Centrum Rijnmond-Zuid, Rotterdam, the Netherlands
¶ Christchurch Hospital, Christchurch, New Zealand
# Academisch Ziekenhuis Middelheim, Antwerp, Belgium
** Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina
Hospital Miguel Perez Carreno, Caracas, Venezuela
Herzzentrum Bodensee, Kreuzlingen, Switzerland
Conor Medsystems, Menlo Park, California
|| || Cardialysis, Rotterdam, the Netherlands
Manuscript received November 30, 2004;
revised manuscript received March 17, 2005,
accepted March 29, 2005.
* Reprint requests and correspondence: Dr. Patrick W. Serruys, Erasmus Medical Center, Thoraxcenter, Bd-406, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
(Email: p.w.j.c.serruys{at}erasmusmc.nl).
OBJECTIVES: The aim of this study was to evaluate the effect of variable dose and release kinetics of paclitaxel on neointimal hyperplasia.
BACKGROUND: Conventional paclitaxel-eluting stents use a durable polymer coating as a vehicle for drug delivery. The Conor stent (Conor Medsystems, Menlo Park, California) with intra-strut wells and erodable polymer is specifically designed for drug delivery with programmable pharmacokinetics.
METHODS: Two hundred and forty-four patients with single vessel disease received either a bare metal Conor stent (n = 53) or one of six different release formulations that varied in dose (10 or 30 µg) and elution release kinetics (first order, zero order), direction (abluminal, luminal), and duration (5, 10, and 30 days). End points at six months (bare stent group) and at four months (eluting stent groups) were angiographic late loss and neointimal tissue volume by intravascular ultrasound and the rate of major adverse cardiac events (MACE).
RESULTS: The lowest in-stent late loss (0.38 mm, p <0.01, and 0.30 mm, p <0.01) and volume obstruction (8%, p <0.01, and 5%, p <0.01) were observed with the 10-µg and 30-µg doses in the 30-day release groups respectively, whereas the highest in-stent late loss (0.88 mm), volume obstruction (26%), and restenosis rate (11.6%) were observed in the bare stent group. The overall MACE rate of the eluting stent group was 8.6%: death 0.5%, myocardial infarction 2.7%, and target lesion revascularization (TLR) 5.3%. Sub-acute thrombosis was 0.5%. The TLR rates in the two 30-day release groups were 0% and 3.4%.
CONCLUSIONS: This novel eluting stent platform, using an erodable polymer with complete elution of low doses of paclitaxel, is safe. The inhibition of the in-stent neointimal hyperplasia was best in the long release groups.
|
Abbreviations and Acronyms
| | DES = drug-eluting stent(s) | | IVUS = intravascular ultrasound | | LV = lumen volume | | MACE = major adverse cardiac events | | MI = myocardial infarction | | MLD = minimal luminal diameter | | PISCES = Paclitaxel In-Stent Controlled Elution Study | | QCA = quantitative coronary angiography | | SV = stroke volume | | TLR = target lesion revascularization | | TVR = target vessel revascularization |
|
This article has been cited by other articles:
|
|
|
|
 
Y. Onuma, P. Serruys, P. den Heijer, K. S. Joesoef, H. Duckers, E. Regar, N. Kukreja, S. Tanimoto, H. M. Garcia-Garcia, H. van Beusekom, et al.
MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses
Eur. Heart J.,
June 2, 2009;
30(12):
1477 - 1485.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Chevalier, S. Silber, S.-J. Park, E. Garcia, G. Schuler, H. Suryapranata, J. Koolen, K. E. Hauptmann, W. Wijns, M.-C. Morice, et al.
Randomized Comparison of the Nobori Biolimus A9-Eluting Coronary Stent With the Taxus Liberte Paclitaxel-Eluting Coronary Stent in Patients With Stenosis in Native Coronary Arteries: The NOBORI 1 Trial--Phase 2
Circ Cardiovasc Interv,
June 1, 2009;
2(3):
188 - 195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Verheye, P. Agostoni, K. D. Dawkins, J. Dens, W. Rutsch, D. Carrie, J. Schofer, C. Lotan, C. L. Dubois, S. A. Cohen, et al.
The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) Trial
J. Am. Coll. Cardiol. Intv.,
March 1, 2009;
2(3):
205 - 214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Krucoff, D. J. Kereiakes, J. L. Petersen, R. Mehran, V. Hasselblad, A. J. Lansky, P. J. Fitzgerald, J. Garg, M. A. Turco, C. A. Simonton III, et al.
A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
J. Am. Coll. Cardiol.,
April 22, 2008;
51(16):
1543 - 1552.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Wessely, A. Kastrati, J. Mehilli, A. Dibra, J. Pache, and A. Schomig
Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design
Eur. Heart J.,
November 2, 2007;
28(22):
2720 - 2725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Windecker and B. Meier
Late Coronary Stent Thrombosis
Circulation,
October 23, 2007;
116(17):
1952 - 1965.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Daemen and P. W. Serruys
Drug-Eluting Stent Update 2007: Part I: A Survey of Current and Future Generation Drug-Eluting Stents: Meaningful Advances or More of the Same?
Circulation,
July 17, 2007;
116(3):
316 - 328.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A H Gershlick and G Richardson
Drug eluting stents
BMJ,
December 16, 2006;
333(7581):
1233 - 1234.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Forrester, M. S. Lee, N. Kapoor, and R. R. Makkar
The Janus Face of Drug-Eluting Stents
J. Am. Coll. Cardiol.,
July 18, 2006;
48(2):
375 - 376.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Colombo and S. J. Corbett
Drug-Eluting Stent Thrombosis: Increasingly Recognized But Too Frequently Overemphasized
J. Am. Coll. Cardiol.,
July 4, 2006;
48(1):
203 - 205.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. W. Serruys
Fourth Annual American College of Cardiology International Lecture: A Journey in the Interventional Field
J. Am. Coll. Cardiol.,
May 2, 2006;
47(9):
1754 - 1768.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Wessely, A. Schomig, and A. Kastrati
Sirolimus and Paclitaxel on Polymer-Based Drug-Eluting Stents: Similar But Different
J. Am. Coll. Cardiol.,
February 21, 2006;
47(4):
708 - 714.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
